| Primary |
| Ovulation Induction |
21.8% |
| In Vitro Fertilisation |
19.0% |
| Infertility |
12.7% |
| Product Used For Unknown Indication |
9.9% |
| Assisted Fertilisation |
8.5% |
| Anovulatory Cycle |
7.0% |
| Infertility Male |
7.0% |
| Infertility Female |
3.5% |
| Oocyte Donation |
3.5% |
| Ovarian Hyperstimulation Syndrome |
2.1% |
| Blood Luteinising Hormone |
1.4% |
| Ovarian Disorder |
1.4% |
| Endometriosis |
0.7% |
| Luteal Phase Deficiency |
0.7% |
| Ovulation Disorder |
0.7% |
|
| Ovarian Hyperstimulation Syndrome |
40.7% |
| Deep Vein Thrombosis |
5.6% |
| Ectopic Pregnancy |
5.6% |
| Exposure During Pregnancy |
5.6% |
| Maternal Exposure During Pregnancy |
5.6% |
| Anaphylactic Reaction |
3.7% |
| Drug Exposure During Pregnancy |
3.7% |
| Non-hodgkin's Lymphoma |
3.7% |
| Ovarian Torsion |
3.7% |
| Pleural Effusion |
3.7% |
| Abdominal Cavity Drainage |
1.9% |
| Abortion Spontaneous |
1.9% |
| Acute Generalised Exanthematous Pustulosis |
1.9% |
| Cerebral Venous Thrombosis |
1.9% |
| Foetal Exposure During Pregnancy |
1.9% |
| Injection Site Pain |
1.9% |
| Irritability |
1.9% |
| Ovarian Enlargement |
1.9% |
| Overdose |
1.9% |
| Pain |
1.9% |
|
| Secondary |
| In Vitro Fertilisation |
31.3% |
| Ovulation Induction |
22.5% |
| Product Used For Unknown Indication |
13.0% |
| Infertility |
6.0% |
| Assisted Fertilisation |
4.7% |
| Ovarian Hyperstimulation Syndrome |
3.5% |
| Anovulatory Cycle |
3.2% |
| Infertility Male |
3.2% |
| Gamete Intrafallopian Transfer |
2.5% |
| Ill-defined Disorder |
1.9% |
| Oocyte Donation |
1.6% |
| Blood Luteinising Hormone |
1.3% |
| Artificial Insemination By Partner |
0.9% |
| Drug Therapy |
0.9% |
| Hormone Therapy |
0.9% |
| Prophylaxis |
0.9% |
| Vitamin Supplementation |
0.6% |
| Infertility Female |
0.3% |
| Luteal Phase Deficiency |
0.3% |
| Ovarian Disorder |
0.3% |
|
| Ovarian Hyperstimulation Syndrome |
33.3% |
| Exposure During Pregnancy |
9.0% |
| Maternal Exposure During Pregnancy |
7.7% |
| Deep Vein Thrombosis |
6.4% |
| Invasive Ductal Breast Carcinoma |
5.1% |
| Ascites |
3.8% |
| Pelvic Fluid Collection |
3.8% |
| Transient Ischaemic Attack |
3.8% |
| Breast Cancer |
2.6% |
| Drug Exposure During Pregnancy |
2.6% |
| Ectopic Pregnancy |
2.6% |
| Foetal Growth Restriction |
2.6% |
| Pain In Extremity |
2.6% |
| Pancreatitis Acute |
2.6% |
| Pulmonary Embolism |
2.6% |
| Thyroiditis |
2.6% |
| Uterine Haemorrhage |
2.6% |
| Acute Generalised Exanthematous Pustulosis |
1.3% |
| Cerebral Infarction |
1.3% |
| Cholestasis Of Pregnancy |
1.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.5% |
| Ovulation Induction |
15.2% |
| Blood Follicle Stimulating Hormone Decreased |
10.1% |
| Blood Luteinising Hormone Decreased |
10.1% |
| In Vitro Fertilisation |
7.6% |
| Crohn's Disease |
6.3% |
| Assisted Fertilisation |
5.1% |
| Infertility Female |
5.1% |
| Infertility |
3.8% |
| Bipolar Disorder |
2.5% |
| Oocyte Donation |
2.5% |
| Abortion Threatened |
1.3% |
| Endometriosis |
1.3% |
| Hypothyroidism |
1.3% |
| Infertility Male |
1.3% |
| Labour Induction |
1.3% |
| Prophylaxis Of Neural Tube Defect |
1.3% |
| Thrombosis Prophylaxis |
1.3% |
| Vulvovaginal Mycotic Infection |
1.3% |
|
| Transverse Presentation |
12.5% |
| Drug Exposure During Pregnancy |
8.3% |
| Drug Ineffective |
8.3% |
| Epilepsy |
8.3% |
| Hot Flush |
8.3% |
| Pain |
8.3% |
| Anaphylactic Reaction |
4.2% |
| Depression |
4.2% |
| Erythema |
4.2% |
| Intra-uterine Death |
4.2% |
| Leukocytoclastic Vasculitis |
4.2% |
| Low Density Lipoprotein Increased |
4.2% |
| Malaise |
4.2% |
| Renal Dysplasia |
4.2% |
| Suicidal Ideation |
4.2% |
| Thrombocytopenia Neonatal |
4.2% |
| Trisomy 18 |
4.2% |
|
| Interacting |
| In Vitro Fertilisation |
100.0% |
|
| Ovarian Hyperstimulation Syndrome |
100.0% |
|
